I am an Independent Consultant with 14 years of commercial experience providing business development consulting services to biotech companies globally. I have strong business development and deal-making experience, incl. a $340M out-licensing deal with Merck, a TCR therapeutics in-licencing deal with Weizmann and £30M of investments in academia and biotech, incl. Swiss biotech GlycoVaxyn that was acquired by GSK for $190M. I have fundraising experience with VCs incl. securing two seed-funding term sheets for new spinout formation in neuroscience and supporting the Achilles Therapeutics £100M Series B financing. I also have extensive operational expertise in cell and gene therapy in cancer, complemented by experience in small molecules in cancer and neuroscience, and vaccines in infectious diseases. I have Board experience and sat on the Board of the Danish biotech Acesion Pharma that recently raised €45M in Series B financing. I am well-networked in Pharma BD and the investor community in UK/EU/US to pursue partnering opportunities. I am a strong leader and team player that strives for operational excellence and acts with integrity and respect. I am resilient, agile, adaptable and thrive in the fast-paced biotech environment whilst being driven by results to develop new therapies for the benefit of patients.I was previously at Achilles Therapeutics, a clinical-stage public biotech developing personalised T cell therapies targeting clonal neoantigens in cancer, where I held senior positions of increasing responsibility to a VP level and contributed to the successful evolution of Achilles from a newco to a mature clinical stage company. I joined the company in 2018 and had first-hand experience of a biotech's growth journey from 20 to 260 employees, incl. £300M fundraising. Prior to Achilles, I was a Partner in Innovations at the Wellcome Trust, a £35BN foundation, investing £100M p.a. in biotech, pharma, and academia globally at the early stages of product development in disease indications of unmet clinical need. I joined Wellcome in 2012 from QM Innovation, the commercialization arm of Queen Mary University of London, a top 10 UK university, where I assisted in commercialization of research and R&D partnerships with pharma.